UroGen Pharma
URGN
URGN
63 hedge funds and large institutions have $413M invested in UroGen Pharma in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
12% less capital invested
Capital invested by funds: $469M → $413M (-$55.9M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Holders
63
Holding in Top 10
3
Calls
$348K
Puts
–
Top Buyers
| 1 | +$10.2M | |
| 2 | +$8.5M | |
| 3 | +$5.59M | |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$3.84M |
| 5 |
DG
Delek Group
Herzliya,
Israel
|
+$2.82M |
Top Sellers
| 1 | -$7.13M | |
| 2 | -$5.32M | |
| 3 | -$888K | |
| 4 |
MAP
Moody Aldrich Partners
Marblehead,
Massachusetts
|
-$860K |
| 5 |
Renaissance Technologies
New York
|
-$793K |